Post Traumatic Stress Disorder, Substance Use Disorders
Conditions
Brief summary
More than 90% of women in substance use treatment report history of physical and/or sexual trauma, and up to 60% meet criteria for both substance use disorder (SUD) and Post Traumatic Stress Disorder (PTSD). PTSD typically precedes onset of SUD, with substances used as a means to cope with physiological, psychological, and emotional symptoms resulting from the trauma. Women with PTSD experience greater severity of addiction symptoms, readmit into treatment more frequently than women without PTSD, and tend to have poorer treatment outcomes. Due to increased risk for exacerbation of PTSD on SUD severity and treatment success, and the specific vulnerabilities and needs of women with this comorbidity, SUD treatments that target both substance use and trauma recovery are needed. However, few interventions target both SUD and PTSD concurrently, and fewer still are specific to women. Mindfulness-Based Relapse Prevention (MBRP) has been shown to decrease craving, relapse rates, and quantity/frequency of use across several substances, and has shown acceptability in diverse populations. MBRP integrates mindfulness practices with cognitive behavioral and exposure-based approaches to increase self-regulatory skills while experiencing triggers previously associated with substance use, including challenging affective states such as those common to experienced trauma. Adapting MBRP to incorporate trauma education and treatment approaches has the potential to effectively treat women with the dual vulnerabilities of trauma history and SUD. The current study is thus designed to determine feasibility, acceptability, and initial efficacy of an adapted Trauma-Informed Mindfulness-Based Relapse Prevention (TI-MBRP) intervention for women in substance use treatment settings who have PTSD. TI-MBRP integrates trauma education and treatment approaches drawn from Cognitive Processing Therapy (CPT) into the standard MBRP protocol to provide a trauma-informed approach to treating women in substance use treatment settings. The current proposal will evaluate TI-MBRP, using a randomized, pre-post design, with 100 women in residential substance abuse treatment. Participants will be randomly assigned to participate in a 4-week TI-MBRP intervention or to continue with treatment as usual (TAU). Assessments will be collected pretest, posttest, and at one-month follow-up. Data from this study will lay the groundwork for a larger scale clinical trial to determine the efficacy of TI-MBRP.
Detailed description
Approximately 4.7 million women in the US experience sexual and/or physical interpersonal violence (IPV) each year, and 46% experience IPV in their lifetime. More than 50% of interpersonal related violence occurs before age 25. In addition to acute, chronic and fatal injuries caused by IPV, women survivors of trauma (WST) are also at greater risk for organ and immune system diseases due to chronic stress, reproductive dysfunctions and complications during pregnancy, psychological disorders, and the inability to access health care services and social support. Estimated medical and mental health care costs for WST are $8.3 billion dollars per year, as well as $8 million dollars lost in paid workdays. Additionally, annual health care cost of survivors can persist up to 15 years after the cessation of abuse. More than 90% of women admitted into substance use treatment settings have experienced IPV, and 30-60% meet criteria for comorbid SUD and PTSD. IPV typically precedes the onset of substance abuse as a means to cope with intense physiological, psychological, and emotional symptoms attributed to the event. Research has demonstrated that for women, PTSD symptoms may mediate the relationship between IPV and problematic SU. Women with PTSD symptoms and SUD also experience greater severity of addiction symptoms compared to men, and often readmit into treatment more frequently than men or women without traumatic histories. Evidence also suggests that PTSD symptoms and SU yields poorer treatment outcomes than any other comorbid disorder, or than SUD or PTSD alone. Due to these high rates of comorbidity and interrelationship of symptoms, particularly in women, integrated treatments targeting both substance use and trauma recovery are needed. However, few such evidence-based interventions (EBIs) are available for WST in substance use treatment settings. The few EBIs addressing SUD and trauma that are available have been mostly validated on males or specifically adapted for veteran populations. Mindfulness-Based Relapse Prevention (MBRP) is one evidence-based intervention that has demonstrated efficacy in reducing substance craving, relapse, and negative affect in a variety of SUD populations. It has also shown efficacy in incarcerated populations, ethnic minority women, and women offenders, all of which have higher levels of trauma exposure compared to normative samples. Research on Mindfulness-Based Interventions (MBIs) with trauma populations suggest that mindfulness skills can help decrease PTSD symptoms associated with avoidance and trauma-based cognitions, and that MBIs are not iatrogenic for trauma populations. A trauma informed adaptation of MBRP may thus offer an integrated intervention targeting both PTSD and SUD symptoms, and addressing the etiologies and maintaining factors underlying the comorbidity. Given the particular needs and unique presentation of WST in substance use treatment settings, effective evidence-based interventions must be developed to improve treatment outcomes. The long-term goal of this line of research is to develop, examine and disseminate an adapted evidence-based treatment for comorbid SUD and PTSD for women survivors of trauma (WST). The primary objective of this study is to develop and evaluate an intervention that integrates trauma education and treatment approaches used in Cognitive Processing Therapy (CPT), an evidence-based intervention for PTSD, into the standard MBRP protocol to provide a trauma-informed approach to treating women in community-based substance use treatment settings. The development phase of the study will use focus groups with staff and clients from a women's residential treatment center who have completed the MBRP course to inform the integration of trauma education using the CPT manual into the MBRP protocol. Using a mixed-methods, pre-post, randomized-control design, WST (N=100) enrolled in a residential treatment program will be randomized by cluster into an experimental (TI-MBRP) or control (TAU) group to determine feasibility, acceptability, preliminary efficacy, and candidate mechanisms of TI-MBRP. To accomplish the primary objective, the following three aims are proposed: Aim 1: Development and refinement of a Trauma Informed-Mindfulness Based Relapse Prevention (TI-MBRP) protocol. Informed by focus groups with staff and resident clients, a protocol integrating evidence-based practices for SUDs and PTSD will be developed for women in substance use treatment endorsing PTSD symptoms. Aim 2: Determine feasibility and acceptability of TI-MBRP. Based on prior studies of MBRP in similar populations, we hypothesize TI-MBRP will be feasible and acceptable, as measured by recruitment and retention rates, weekly homework compliance, client participation in groups, and post-intervention client feedback. Aim 3: Determine meaningful changes at pre-, post-, 1-, 3-, 6-, 9-, and 12-month follow-up assessment time points in SUD and trauma-related outcomes, and identify candidate mechanisms. We hypothesize that, as compared to TAU, participation in TI-MBRP will result in: 1. Significantly reduced trauma-related symptomology, craving, substance use, reactivity to negative affect, and experiential avoidance at post-intervention, and maintenance of treatment outcomes at 12-month follow-up. 2. Significant improvements in self-efficacy, coping skills, and mindfulness at post-intervention, and maintenance of treatment outcomes at 12-month follow-up. Interested residents will be screened for eligibility based on the Inclusion/Exclusion Screening Tool, Breslau's Short Screening Scale, and Suicidal Behaviors Questionnaire. Eligible participants will be provided with a written informed consent. The PI will review the informed consent with participants and answer any questions or concerns that participants may have about study procedures, confidentiality, data analysis, and dissemination of results. Once written informed consent is obtained, participants will be notified of the group start date within one week of signing the consent form. Participants will be asked to complete a battery of paper-and-pencil assessments within one week prior to the start of the first session. Paper-and-pencil assessments will take no more than 60 minutes to complete. Experimental and Treatment-As-Usual (TAU) groups will be implemented simultaneously for maximization of participants within the given time frame, totaling 10 groups over a 10-month period. Participants will complete a battery of self-report assessments at baseline. Then, using computer randomizing software, participants will be randomized by cluster into either an experimental or TAU group before the start of the first session. After the first session, all participants will be given an iPod touch with audio-recordings of guided meditation practices used in the intervention (i.e., body scan, breath awareness) to use as a part of their daily homework requirements. All iPod touch devices will include iMINDr, a software application developed to track frequency and duration of home meditation practice. Participants will then complete a post-course assessment battery within one week of the completion of the 4-week course. If participants are unable to be physically present to complete the post-course assessment, they will be offered a phone interview during which they will be administered self-report assessment measures orally. One week after post-course assessment, participants will be invited to participate in an hour long, audio-recorded focus group to discuss helpful aspects of the intervention as well as what could be changed. Focus group audio recordings will be transcribed verbatim and analyzed in NVivo 11 by independent coders using a Constant Comparative Analysis. Participants will be asked to complete additional paper-and-pencil assessments at 1-, 3-, 6-, 9-, and 12-months following post course. If participants are unable to physically attend follow-up assessment, they will be offered a phone interview with self-report assessments administered orally.
Interventions
BEHAVIORALTrauma Informed Mindfulness-Based Relapse Prevention
Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
BEHAVIORALTreatment As Usual (TAU)
The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
Sponsors
Pacific University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
Participants were made unaware of whether they were being randomized to the treatment or control group condition.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* 1\) Be in the core learning phase of treatment at the Women's Residential Center (WRC) * 2\) Have a score of at least 4 on Breslau's Short Screening Scale for PTSD * 3\) Be age 18 to 70 * 4\) Be fluent in speaking and reading English * 5\) Agree to randomization and attendance at treatment and assessment sessions * 6\) Be cleared for participation by appropriate clinic staff
Exclusion criteria
* 1\) Report active suicidality as indicated by endorsing Yes to questions 5d - 5f in the Inclusion Exclusion Screening Form. * 2\) Endorse screening items indicating hallucinations or intense emotional lability * 3\) Have previously participated in an MBRP group in current or past treatment settings * 4\) Are in the stabilization or transition phase, versus core learning phase, of treatment * 5\) Fail to provide informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks | This self-report measure assesses frequency of alcohol and substance use, and misuse of prescription medication over the past 2 weeks, 30 days, and 3 months. Items are on a Likert scale, where 0 = Not at all, 1 = One or two days, 2 = Several days, 3 = More than half the days, and 4 = Nearly every day. Total scare scores range from 0 - 44. Higher scores indicate greater frequency of use. |
| Recruitment | Baseline | Number of participants who completed informed consent and screening, with at least 30% identifying as racial and/or ethnic minority. |
| Enrollment | Baseline | Percentage of eligible individuals who completed baseline measures. |
| Retention | 8-weeks | Percentage of participants who completed 1-month follow-up measures. |
| Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks | 20-item screening instrument assessing PTSD symptoms. Each item is scored 0 - 4 (0 = Not at all, 1 = A little bit, 2 = Moderately, 3 = Quite a bit, 4 = Extremely). Total scores range from 0 - 80. Higher values indicate greater PTSD symptom severity. |
| Craving by the Penn Alcohol Craving Scale (PACS) Scores | Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks | 5 items assessing frequency, intensity, and duration of alcohol or drug craving. Each item is scored 0-6 (0 = Never, 1 = Rarely , 2 = Occasionally , 3 = Sometimes, 4 = Often, 5 = Most of the time, 6 = Nearly all the time). Total scale scores range from 0 - 30. Higher scores indicate greater severity of alcohol and substance craving. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks | 36-item self-report measure of reaction to negative affect. This measure contains 6 subscales and a total score, and only the 6-item non-acceptance of emotion subscale (α = 0.85) was be used, which measures the degree to which an individual accepts their reaction to negative emotions. Items are scaled from 1 - 6, where 1 = Almost never (1 - 10%), 2 = Sometimes (11 - 35%), 3 = About half the time (36 - 65%), 4 = Most of the time (66 - 90%), and 5 = Almost always (91 - 99%). Total subscale scores range from 6 to 30. Higher scores indicate less acceptance of negative affective states. |
| Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks | 24-item, self-report measure of mindfulness. The FFMQ-SF contains a total mindfulness score and 5 subscale scores measuring awareness, non-judgment, describing, observing, and non-reactivity. Items are scaled from 1 - 5, where 1 = Never or very rarely true, 2 = Rarely true, 3 = Sometimes true, 4 = Often true, and 5 = Very often or always true. Subscale scores are combined to achieve a total score, which are presented in the data table below. Total scores range from 24 to 120. Higher scores indicate greater levels of mindfulness. |
| Coping Responses Inventory (CRI) | Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks | The CRI is a self-report, 48-item questionnaire assessing coping resources in stressful situations, with subscales measuring approach-based coping and avoidant coping in difficult situations. Items are on a 4-point Likert scale varying from Not at all to Fairly often. Subscale scores on approach- and avoidant-based coping range from 0 to 72, and each contain 24 items. Higher scores on the approach-based coping subscale indicates greater use of approach-based coping strategies when faced with a stressor. Higher scores on the avoidance-based coping subscale indicates greater use of avoidant-based coping strategies when faced with a stressor. |
| Drug Taking Confidence Questionnaire | Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks | 8-item brief self-report questionnaire measuring confidence in avoiding, abstaining or moderating substance use across 8 categories of relapse precipitants. Items are scaled from 0 - 100 in increments of 20, where 0 = Not confident at all and 100 = Very confident. |
| Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks | 18-item self-report measure of experiential avoidance and psychological inflexibility related to substance abuse behaviors. Each item is scaled from 1 - 7, where 1 = Never true, 2 = Very seldom true, 3 = Seldom true, 4 = Sometimes true, 5 = Frequently true, 6 = Almost always true, and 7 = Always true. Total scores range from 18 to 126. Higher scores indicate less psychological flexibility with regard to substance use. |
Countries
United States
Participant flow
Recruitment details
Participants were recruited from community-based residential and intensive outpatient chemical dependency treatment centers in the Pacific Northwest. Facilities included three residential and two IOP clinics. Approximately 95% of women within these treatment facilities had a lifetime history of trauma, and approximately 88% were dually diagnosed with PTSD. Counselors and administrators assisted with recruitment via word of mouth, flyers, and announcements at weekly group meetings.
Pre-assignment details
Participants who enrolled in the study agreed to complete an informed consent and screening procedure. Those who were eligible via our screening procedure completed baseline assessments prior to group assignment.
Participants by arm
| Arm | Count |
|---|---|
| TI-MBRP Trauma-Integrated Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT), and gender-responsive interventions, into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance use, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events. Moreover, gender-focused themes will be discussed in relation to SUD and PTSD recovery such as parenting, interpersonal relationships, and empowerment. | 38 |
| Standard MBRP The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use. | 45 |
| Total | 83 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Discharged from treatment | 3 | 6 |
| Overall Study | Lost to Follow-up | 7 | 11 |
| Overall Study | Withdrawal by Subject | 6 | 0 |
Baseline characteristics
| Characteristic | TI-MBRP | Total | Standard MBRP |
|---|---|---|---|
| Age, Continuous | 37.22 years STANDARD_DEVIATION 10.28 | 34.67 years STANDARD_DEVIATION 9.27 | 32.55 years STANDARD_DEVIATION 7.86 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 8 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 33 Participants | 73 Participants | 40 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 3 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 4 Participants | 7 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 6 Participants | 5 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 8 Participants | 6 Participants |
| Race (NIH/OMB) White | 30 Participants | 59 Participants | 29 Participants |
| Region of Enrollment United States | 38 participants | 83 participants | 45 participants |
| Sex: Female, Male Female | 38 Participants | 83 Participants | 45 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 38 | 0 / 45 |
| other Total, other adverse events | 0 / 38 | 0 / 45 |
| serious Total, serious adverse events | 0 / 38 | 0 / 45 |
Outcome results
Primary
Craving by the Penn Alcohol Craving Scale (PACS) Scores
5 items assessing frequency, intensity, and duration of alcohol or drug craving. Each item is scored 0-6 (0 = Never, 1 = Rarely , 2 = Occasionally , 3 = Sometimes, 4 = Often, 5 = Most of the time, 6 = Nearly all the time). Total scale scores range from 0 - 30. Higher scores indicate greater severity of alcohol and substance craving.
Time frame: Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks
Population: Women with PTSD and substance use disorder.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Women Who Were Interested in Participation | Craving by the Penn Alcohol Craving Scale (PACS) Scores | 4-weeks | 8.33 score on a scale | Standard Deviation 5.51 |
| All Women Who Were Interested in Participation | Craving by the Penn Alcohol Craving Scale (PACS) Scores | 24-weeks | 9.30 score on a scale | Standard Deviation 7.41 |
| All Women Who Were Interested in Participation | Craving by the Penn Alcohol Craving Scale (PACS) Scores | 8-weeks | 8.00 score on a scale | Standard Deviation 5.03 |
| All Women Who Were Interested in Participation | Craving by the Penn Alcohol Craving Scale (PACS) Scores | 36-weeks | 8.67 score on a scale | Standard Deviation 7.85 |
| All Women Who Were Interested in Participation | Craving by the Penn Alcohol Craving Scale (PACS) Scores | Baseline | 20.5 score on a scale | Standard Deviation 7.76 |
| All Women Who Were Interested in Participation | Craving by the Penn Alcohol Craving Scale (PACS) Scores | 52-weeks | 8.07 score on a scale | Standard Deviation 6.19 |
| All Women Who Were Interested in Participation | Craving by the Penn Alcohol Craving Scale (PACS) Scores | 12-weeks | 7.38 score on a scale | Standard Deviation 5.04 |
| Standard MBRP | Craving by the Penn Alcohol Craving Scale (PACS) Scores | 52-weeks | 9.15 score on a scale | Standard Deviation 7.69 |
| Standard MBRP | Craving by the Penn Alcohol Craving Scale (PACS) Scores | Baseline | 21.31 score on a scale | Standard Deviation 8.71 |
| Standard MBRP | Craving by the Penn Alcohol Craving Scale (PACS) Scores | 8-weeks | 6.86 score on a scale | Standard Deviation 7.14 |
| Standard MBRP | Craving by the Penn Alcohol Craving Scale (PACS) Scores | 12-weeks | 7.18 score on a scale | Standard Deviation 6.61 |
| Standard MBRP | Craving by the Penn Alcohol Craving Scale (PACS) Scores | 24-weeks | 5.15 score on a scale | Standard Deviation 4.71 |
| Standard MBRP | Craving by the Penn Alcohol Craving Scale (PACS) Scores | 36-weeks | 9.33 score on a scale | Standard Deviation 7.61 |
| Standard MBRP | Craving by the Penn Alcohol Craving Scale (PACS) Scores | 4-weeks | 10.36 score on a scale | Standard Deviation 8.48 |
Primary
Enrollment
Percentage of eligible individuals who completed baseline measures.
Time frame: Baseline
Population: Women with comorbid PTSD and substance use disorder.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Women Who Were Interested in Participation | Enrollment | 83 Participants |
Primary
Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores
This self-report measure assesses frequency of alcohol and substance use, and misuse of prescription medication over the past 2 weeks, 30 days, and 3 months. Items are on a Likert scale, where 0 = Not at all, 1 = One or two days, 2 = Several days, 3 = More than half the days, and 4 = Nearly every day. Total scare scores range from 0 - 44. Higher scores indicate greater frequency of use.
Time frame: Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Women Who Were Interested in Participation | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | 8-weeks | .333 score on a scale | Standard Deviation 0.707 |
| All Women Who Were Interested in Participation | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | 24-weeks | 0.00 score on a scale | Standard Deviation 0 |
| All Women Who Were Interested in Participation | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | 4-weeks | .454 score on a scale | Standard Deviation 1.51 |
| All Women Who Were Interested in Participation | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | 36-weeks | 2.36 score on a scale | Standard Deviation 5.92 |
| All Women Who Were Interested in Participation | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | 12-weeks | .118 score on a scale | Standard Deviation 0.332 |
| All Women Who Were Interested in Participation | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | 52-weeks | 4.14 score on a scale | Standard Deviation 11.62 |
| All Women Who Were Interested in Participation | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | Baseline | .421 score on a scale | Standard Deviation 1.26 |
| Standard MBRP | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | 52-weeks | .846 score on a scale | Standard Deviation 2.51 |
| Standard MBRP | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | Baseline | 1.15 score on a scale | Standard Deviation 2.67 |
| Standard MBRP | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | 4-weeks | .105 score on a scale | Standard Deviation 0.459 |
| Standard MBRP | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | 8-weeks | .000 score on a scale | Standard Deviation 0 |
| Standard MBRP | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | 12-weeks | .278 score on a scale | Standard Deviation 1.18 |
| Standard MBRP | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | 24-weeks | 0.00 score on a scale | Standard Deviation 0 |
| Standard MBRP | Frequency of Alcohol and Substance Use by the NIDA Alcohol, Smoking, and Substance Involvement Test (ASSIST) Scores | 36-weeks | .111 score on a scale | Standard Deviation 0.333 |
Primary
Recruitment
Number of participants who completed informed consent and screening, with at least 30% identifying as racial and/or ethnic minority.
Time frame: Baseline
Population: Women in residential or intensive outpatient treatment substance use treatment from one of five clinics participating in the study during the time of study recruitment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Women Who Were Interested in Participation | Recruitment | 96 Participants |
Primary
Retention
Percentage of participants who completed 1-month follow-up measures.
Time frame: 8-weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Women Who Were Interested in Participation | Retention | 22 Participants |
| Standard MBRP | Retention | 28 Participants |
Primary
Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores
20-item screening instrument assessing PTSD symptoms. Each item is scored 0 - 4 (0 = Not at all, 1 = A little bit, 2 = Moderately, 3 = Quite a bit, 4 = Extremely). Total scores range from 0 - 80. Higher values indicate greater PTSD symptom severity.
Time frame: Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks
Population: Women with comorbid PTSD and Substance Use Disorder
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Women Who Were Interested in Participation | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | 8-weeks | 28.75 score on a scale | Standard Deviation 14.98 |
| All Women Who Were Interested in Participation | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | 24-weeks | 33.53 score on a scale | Standard Deviation 18.5 |
| All Women Who Were Interested in Participation | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | 4-weeks | 35.41 score on a scale | Standard Deviation 15.79 |
| All Women Who Were Interested in Participation | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | 36-weeks | 27.67 score on a scale | Standard Deviation 16.73 |
| All Women Who Were Interested in Participation | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | 12-weeks | 30.17 score on a scale | Standard Deviation 15.66 |
| All Women Who Were Interested in Participation | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | 52-weeks | 28.21 score on a scale | Standard Deviation 21.01 |
| All Women Who Were Interested in Participation | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | Baseline | 43.51 score on a scale | Standard Deviation 15.28 |
| Standard MBRP | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | 52-weeks | 28.69 score on a scale | Standard Deviation 19.37 |
| Standard MBRP | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | Baseline | 48.55 score on a scale | Standard Deviation 14.39 |
| Standard MBRP | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | 4-weeks | 30.50 score on a scale | Standard Deviation 13.86 |
| Standard MBRP | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | 8-weeks | 21.82 score on a scale | Standard Deviation 14.32 |
| Standard MBRP | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | 12-weeks | 27.04 score on a scale | Standard Deviation 16.5 |
| Standard MBRP | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | 24-weeks | 29.84 score on a scale | Standard Deviation 17.21 |
| Standard MBRP | Trauma Symptoms by the Posttraumatic Checklist - Civilian (PCL-5) Scores | 36-weeks | 29.11 score on a scale | Standard Deviation 14.72 |
Secondary
Coping Responses Inventory (CRI)
The CRI is a self-report, 48-item questionnaire assessing coping resources in stressful situations, with subscales measuring approach-based coping and avoidant coping in difficult situations. Items are on a 4-point Likert scale varying from Not at all to Fairly often. Subscale scores on approach- and avoidant-based coping range from 0 to 72, and each contain 24 items. Higher scores on the approach-based coping subscale indicates greater use of approach-based coping strategies when faced with a stressor. Higher scores on the avoidance-based coping subscale indicates greater use of avoidant-based coping strategies when faced with a stressor.
Time frame: Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | Baseline Avoidance | 15.72 score on a scale | Standard Deviation 9.89 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | Baseline Approach | 23.52 score on a scale | Standard Deviation 15.58 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | 4-weeks Avoidance | 14.97 score on a scale | Standard Deviation 8.64 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | 4-weeks Approach | 27.80 score on a scale | Standard Deviation 10.89 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | 8-weeks Avoidance | 12.50 score on a scale | Standard Deviation 9.5 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | 8-weeks Approach | 28.68 score on a scale | Standard Deviation 13.7 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | 12-weeks Avoidance | 30.52 score on a scale | Standard Deviation 11.01 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | 12-weeks Approach | 50.41 score on a scale | Standard Deviation 9.51 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | 24-weeks Avoidance | 26.00 score on a scale | Standard Deviation 8.4 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | 24-weeks Approach | 44.83 score on a scale | Standard Deviation 13.66 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | 36-weeks Avoidance | 23.33 score on a scale | Standard Deviation 6.98 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | 36-weeks Approach | 43.20 score on a scale | Standard Deviation 13.43 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | 52-weeks Avoidance | 22.86 score on a scale | Standard Deviation 9.2 |
| All Women Who Were Interested in Participation | Coping Responses Inventory (CRI) | 52-weeks Approach | 44.21 score on a scale | Standard Deviation 12.04 |
| Standard MBRP | Coping Responses Inventory (CRI) | 36-weeks Avoidance | 22.67 score on a scale | Standard Deviation 6.52 |
| Standard MBRP | Coping Responses Inventory (CRI) | Baseline Avoidance | 22.05 score on a scale | Standard Deviation 14.07 |
| Standard MBRP | Coping Responses Inventory (CRI) | 12-weeks Approach | 48.57 score on a scale | Standard Deviation 13.41 |
| Standard MBRP | Coping Responses Inventory (CRI) | Baseline Approach | 28.77 score on a scale | Standard Deviation 17.36 |
| Standard MBRP | Coping Responses Inventory (CRI) | 52-weeks Avoidance | 30.54 score on a scale | Standard Deviation 13.84 |
| Standard MBRP | Coping Responses Inventory (CRI) | 4-weeks Avoidance | 16.51 score on a scale | Standard Deviation 11.56 |
| Standard MBRP | Coping Responses Inventory (CRI) | 24-weeks Avoidance | 23.85 score on a scale | Standard Deviation 6.96 |
| Standard MBRP | Coping Responses Inventory (CRI) | 4-weeks Approach | 31.27 score on a scale | Standard Deviation 16.36 |
| Standard MBRP | Coping Responses Inventory (CRI) | 36-weeks Approach | 46.22 score on a scale | Standard Deviation 15.17 |
| Standard MBRP | Coping Responses Inventory (CRI) | 8-weeks Avoidance | 15.03 score on a scale | Standard Deviation 10.46 |
| Standard MBRP | Coping Responses Inventory (CRI) | 24-weeks Approach | 50.54 score on a scale | Standard Deviation 12.73 |
| Standard MBRP | Coping Responses Inventory (CRI) | 8-weeks Approach | 33.14 score on a scale | Standard Deviation 18.07 |
| Standard MBRP | Coping Responses Inventory (CRI) | 52-weeks Approach | 50.84 score on a scale | Standard Deviation 12.27 |
| Standard MBRP | Coping Responses Inventory (CRI) | 12-weeks Avoidance | 28.41 score on a scale | Standard Deviation 9.53 |
Secondary
Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA)
36-item self-report measure of reaction to negative affect. This measure contains 6 subscales and a total score, and only the 6-item non-acceptance of emotion subscale (α = 0.85) was be used, which measures the degree to which an individual accepts their reaction to negative emotions. Items are scaled from 1 - 6, where 1 = Almost never (1 - 10%), 2 = Sometimes (11 - 35%), 3 = About half the time (36 - 65%), 4 = Most of the time (66 - 90%), and 5 = Almost always (91 - 99%). Total subscale scores range from 6 to 30. Higher scores indicate less acceptance of negative affective states.
Time frame: Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Women Who Were Interested in Participation | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | 8-weeks | 14.26 score on a scale | Standard Deviation 6.73 |
| All Women Who Were Interested in Participation | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | 24-weeks | 13.70 score on a scale | Standard Deviation 5.06 |
| All Women Who Were Interested in Participation | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | 4-weeks | 14.66 score on a scale | Standard Deviation 4.32 |
| All Women Who Were Interested in Participation | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | 36-weeks | 13.07 score on a scale | Standard Deviation 7.07 |
| All Women Who Were Interested in Participation | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | 12-weeks | 14.62 score on a scale | Standard Deviation 5.55 |
| All Women Who Were Interested in Participation | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | 52-weeks | 12.00 score on a scale | Standard Deviation 5.52 |
| All Women Who Were Interested in Participation | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | Baseline | 17.10 score on a scale | Standard Deviation 5.59 |
| Standard MBRP | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | 52-weeks | 11.53 score on a scale | Standard Deviation 4.39 |
| Standard MBRP | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | Baseline | 17.55 score on a scale | Standard Deviation 5.83 |
| Standard MBRP | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | 4-weeks | 13.27 score on a scale | Standard Deviation 5.04 |
| Standard MBRP | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | 8-weeks | 11.77 score on a scale | Standard Deviation 4.92 |
| Standard MBRP | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | 12-weeks | 10.86 score on a scale | Standard Deviation 5.55 |
| Standard MBRP | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | 24-weeks | 10.92 score on a scale | Standard Deviation 4.8 |
| Standard MBRP | Difficulties in Emotion Regulation Scale - Non-acceptance (DERS-NA) | 36-weeks | 11.78 score on a scale | Standard Deviation 5.33 |
Secondary
Drug Taking Confidence Questionnaire
8-item brief self-report questionnaire measuring confidence in avoiding, abstaining or moderating substance use across 8 categories of relapse precipitants. Items are scaled from 0 - 100 in increments of 20, where 0 = Not confident at all and 100 = Very confident.
Time frame: Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Women Who Were Interested in Participation | Drug Taking Confidence Questionnaire | 52-weeks | 62.14 percentage of confidence in abstaining | Standard Deviation 20.63 |
| All Women Who Were Interested in Participation | Drug Taking Confidence Questionnaire | Baseline | 43.36 percentage of confidence in abstaining | Standard Deviation 21.58 |
| All Women Who Were Interested in Participation | Drug Taking Confidence Questionnaire | 8-weeks | 55.97 percentage of confidence in abstaining | Standard Deviation 23.68 |
| All Women Who Were Interested in Participation | Drug Taking Confidence Questionnaire | 12-weeks | 63.17 percentage of confidence in abstaining | Standard Deviation 15.75 |
| All Women Who Were Interested in Participation | Drug Taking Confidence Questionnaire | 24-weeks | 55.60 percentage of confidence in abstaining | Standard Deviation 22.01 |
| All Women Who Were Interested in Participation | Drug Taking Confidence Questionnaire | 36-weeks | 62.27 percentage of confidence in abstaining | Standard Deviation 21.93 |
| All Women Who Were Interested in Participation | Drug Taking Confidence Questionnaire | 4-weeks | 57.05 percentage of confidence in abstaining | Standard Deviation 19.12 |
| Standard MBRP | Drug Taking Confidence Questionnaire | 24-weeks | 65.08 percentage of confidence in abstaining | Standard Deviation 20.8 |
| Standard MBRP | Drug Taking Confidence Questionnaire | 52-weeks | 67.85 percentage of confidence in abstaining | Standard Deviation 12.59 |
| Standard MBRP | Drug Taking Confidence Questionnaire | 12-weeks | 63.23 percentage of confidence in abstaining | Standard Deviation 24.18 |
| Standard MBRP | Drug Taking Confidence Questionnaire | Baseline | 39.87 percentage of confidence in abstaining | Standard Deviation 27.33 |
| Standard MBRP | Drug Taking Confidence Questionnaire | 4-weeks | 61.22 percentage of confidence in abstaining | Standard Deviation 20.98 |
| Standard MBRP | Drug Taking Confidence Questionnaire | 36-weeks | 72.00 percentage of confidence in abstaining | Standard Deviation 10.15 |
| Standard MBRP | Drug Taking Confidence Questionnaire | 8-weeks | 65.46 percentage of confidence in abstaining | Standard Deviation 19.37 |
Secondary
Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF)
24-item, self-report measure of mindfulness. The FFMQ-SF contains a total mindfulness score and 5 subscale scores measuring awareness, non-judgment, describing, observing, and non-reactivity. Items are scaled from 1 - 5, where 1 = Never or very rarely true, 2 = Rarely true, 3 = Sometimes true, 4 = Often true, and 5 = Very often or always true. Subscale scores are combined to achieve a total score, which are presented in the data table below. Total scores range from 24 to 120. Higher scores indicate greater levels of mindfulness.
Time frame: Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Women Who Were Interested in Participation | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | 8-weeks | 82.50 score on a scale | Standard Deviation 8.87 |
| All Women Who Were Interested in Participation | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | 24-weeks | 80.77 score on a scale | Standard Deviation 12.13 |
| All Women Who Were Interested in Participation | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | 4-weeks | 78.19 score on a scale | Standard Deviation 11.03 |
| All Women Who Were Interested in Participation | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | 36-weeks | 88.53 score on a scale | Standard Deviation 14.05 |
| All Women Who Were Interested in Participation | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | 12-weeks | 80.29 score on a scale | Standard Deviation 12.48 |
| All Women Who Were Interested in Participation | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | 52-weeks | 88.00 score on a scale | Standard Deviation 12.27 |
| All Women Who Were Interested in Participation | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | Baseline | 74.48 score on a scale | Standard Deviation 11.85 |
| Standard MBRP | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | 52-weeks | 91.38 score on a scale | Standard Deviation 15.86 |
| Standard MBRP | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | Baseline | 72.71 score on a scale | Standard Deviation 10.41 |
| Standard MBRP | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | 4-weeks | 81.00 score on a scale | Standard Deviation 12.65 |
| Standard MBRP | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | 8-weeks | 88.10 score on a scale | Standard Deviation 12.2 |
| Standard MBRP | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | 12-weeks | 88.50 score on a scale | Standard Deviation 14.49 |
| Standard MBRP | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | 24-weeks | 93.69 score on a scale | Standard Deviation 13.57 |
| Standard MBRP | Five Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) | 36-weeks | 88.44 score on a scale | Standard Deviation 12.96 |
Secondary
Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores
18-item self-report measure of experiential avoidance and psychological inflexibility related to substance abuse behaviors. Each item is scaled from 1 - 7, where 1 = Never true, 2 = Very seldom true, 3 = Seldom true, 4 = Sometimes true, 5 = Frequently true, 6 = Almost always true, and 7 = Always true. Total scores range from 18 to 126. Higher scores indicate less psychological flexibility with regard to substance use.
Time frame: Baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks, 36-weeks, 52-weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| All Women Who Were Interested in Participation | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | 8-weeks | 97.77 score on a scale | Standard Deviation 14.53 |
| All Women Who Were Interested in Participation | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | 24-weeks | 89.69 score on a scale | Standard Deviation 31.67 |
| All Women Who Were Interested in Participation | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | 4-weeks | 94.19 score on a scale | Standard Deviation 15.64 |
| All Women Who Were Interested in Participation | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | 36-weeks | 101.93 score on a scale | Standard Deviation 21.35 |
| All Women Who Were Interested in Participation | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | 12-weeks | 99.12 score on a scale | Standard Deviation 16.07 |
| All Women Who Were Interested in Participation | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | 52-weeks | 103.79 score on a scale | Standard Deviation 20.98 |
| All Women Who Were Interested in Participation | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | Baseline | 84.13 score on a scale | Standard Deviation 19.09 |
| Standard MBRP | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | 52-weeks | 107.08 score on a scale | Standard Deviation 13.35 |
| Standard MBRP | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | Baseline | 87.36 score on a scale | Standard Deviation 18.43 |
| Standard MBRP | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | 4-weeks | 100.37 score on a scale | Standard Deviation 13.86 |
| Standard MBRP | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | 8-weeks | 105.5 score on a scale | Standard Deviation 13.49 |
| Standard MBRP | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | 12-weeks | 107.86 score on a scale | Standard Deviation 13.75 |
| Standard MBRP | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | 24-weeks | 109.38 score on a scale | Standard Deviation 12.45 |
| Standard MBRP | Psychological Inflexibility and Experiential Avoidance by the Acceptance and Action Questionnaire - Substance Abuse (AAQ-SA) Scores | 36-weeks | 110.22 score on a scale | Standard Deviation 11.61 |